<DOC>
	<DOCNO>NCT00846495</DOCNO>
	<brief_summary>Subjects enrol 2 investigative site complete 3 visit . Following Visit 1 , 1-month Baseline Period , subject treat usual medication document warn sign ( Prodrome pre-headache ) migraine occur . Following randomization ( like flip coin ) Visit 2 , subject treat daily topiramate Prodrome frovatriptan . Subjects complete 2-month Treatment Period exit Visit 3.This study compare effectiveness daily treatment vs. treatment pre-headache phase prevention migraine .</brief_summary>
	<brief_title>Pilot Study Compare Frovatriptan vs. Topiramate Prevention Migraine</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<mesh_term>Frovatriptan</mesh_term>
	<criteria>INCLUSION CRITERIA 1 . Subject least oneyear history migraine without aura meeting International Headache Society criterion ( see Appendix ) 2 . Subject 3month history average 36 migraine per month 3 . Subject report premonitory symptom ability predict least 50 % high impact headache 4 . Subjects must currently past successfully utilized triptan acute treatment migraine determine investigator . 5 . Male female least 18 year age 6 . Subject childbearing potential agrees use adequate contraception study . Adequate method contraception determine investigator consistent contraceptive care administer regular clinical use frovatriptan topiramate . 7 . Subject aware prodrome symptom may include physiological , psychological cognitive change . These may include , limited symptom PreMenstrual Syndrome ( PMS ) , change mood , energy level , appetite , food craving , nausea , sense hearing , sense smell swelling/fluid retention , excessive yawning , head pain , muscle pain/tenderness , irritability , confusion , extreme sleepiness , impaired speech impaired memory . ( The subject able differentiate symptom similar symptom precede migraine ) . The symptom precede migraine 424 hour signal impend migraine attack . 8 . Subject able understand instruction study complete diary 9 . Subject willing give inform consent participate study 10 . Any migraine prophylactic medication must stabilize dosage one month EXCLUSION CRITERIA 1 . History medical condition would confound result study include limited following : Hepatic disease significant hepatic dysfunction History pancreatitis History thrombocytopenia History glaucoma History osteoporosis osteopenia Cardiovascular Disease Coronary artery disease , Ischemic heart disease Significant Arrhythmia History active Cerebrovascular Disease Hypertension Uncontrolled hypertension nonmigrainous state ( &gt; 160 mmHg systolic &gt; 95 mmHg . diastolic ) . Hypertension must control effectively medication period 3 month . Basilar Hemiplegic Migraine Significant peripheral vascular disease Raynaud 's Syndrome Significant Active Renal , Hepatic , Gastrointestinal , Endocrine Neurological Disease History depression , mood problem suicidal thought behavior opinion Investigator would interfere participation study . 2 . History ergotamine , `` triptan '' , analgesic abuse within past 3 month 3 . History current recent drug alcohol abuse would interfere participation study . 4 . More 15 headache day per month within past 3 month . 5 . Women pregnant breast feed 6 . Subjects know hypersensitivity intolerance topiramate triptanlike medication 7 . Subject schedule surgical procedure occur enrol study.that opinion Investigator would interfere participation study . 8 . Subject ketogenic diet 9 . Participation another investigative drug study within previous 30 day 10 . Excluded medication : MAO Inhibitors , lithium , methylergonovine , methysergide , ergotaminecontaining product , topiramate daily migraine prophylaxis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Migraine</keyword>
	<keyword>Migraine prevention</keyword>
	<keyword>Prodrome</keyword>
	<keyword>Premonitory phase</keyword>
	<keyword>Preemptive therapy</keyword>
</DOC>